fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 34. More products

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Fosamax (02201038), Co Alendronate (02258102). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Alendronate

19 general benefit · 5 not a benefit

Alendronate Sodium Tablets · DIN 02381486 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Alendronate Sodium Tablets · DIN 02381486 Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-03-20 · brand ACH-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Alendronate Sodium Tablets: Formulary list price $0.50 per unit (the source does not state the unit; exact figure $0.4987). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02381486)

Source record
DIN 02381486: Alendronate Sodium Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 920000232; group id 891; item number 2141; lccId None; manufacturer id ACH Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4987; ministry $0.4987 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02381486 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86733
Interchangeable products
Apo-Alendronate · DIN 02248728 · $0.4987 Auro-Alendronate · DIN 02388545 · $0.4987 Fosamax · DIN 02201011 · not recorded Mint-Alendronate · DIN 02394863 · $0.4987 Ran-Alendronate · DIN 02384701 · $0.4987 Sandoz Alendronate · DIN 02288087 · $0.4987 Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: active shortage (reported April 12, 2024, last updated April 13, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381486
Shortage record checked October 6, 2026

Auro-Alendronate · DIN 02388545 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Alendronate · DIN 02388545 Manufacturer: Auro Pharma Inc.; listing date 2012-09-28 Health Canada: Marketed since 2012-07-26 · brand AURO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Alendronate: Formulary list price $0.50 per unit (the source does not state the unit; exact figure $0.4987). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388545)

Source record
DIN 02388545: Auro-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000232; group id 891; item number 2141; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4987; ministry $0.4987 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388545 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87407
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987 Apo-Alendronate · DIN 02248728 · $0.4987 Fosamax · DIN 02201011 · not recorded Mint-Alendronate · DIN 02394863 · $0.4987 Ran-Alendronate · DIN 02384701 · $0.4987 Sandoz Alendronate · DIN 02288087 · $0.4987 Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: resolved shortage (ended October 15, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388545
Shortage record checked October 6, 2026

Alendronate · DIN 02299712 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Alendronate · DIN 02299712 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2009-11-19 Health Canada: Marketed since 2022-01-27 · brand ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02299712)

Source record
DIN 02299712: Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id SIV Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02299712 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78508
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended April 1, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299712
Shortage record checked October 6, 2026

Alendronate · DIN 02352966 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Alendronate · DIN 02352966 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2026-02-25 · brand ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02352966)

Source record
DIN 02352966: Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id SAI Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352966 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83819
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended April 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352966
Shortage record checked October 6, 2026

Alendronate Sodium Tablets · DIN 02381494 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Alendronate Sodium Tablets · DIN 02381494 Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-03-20 · brand ACH-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Alendronate Sodium Tablets: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02381494)

Source record
DIN 02381494: Alendronate Sodium Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id ACH Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02381494 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86734
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended February 13, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381494
Shortage record checked October 6, 2026

Apo-Alendronate · DIN 02248730 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Alendronate · DIN 02248730 Manufacturer: Apotex Inc.; listing date 2005-07-14 Health Canada: Marketed since 2005-05-27 · brand APO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248730)

Source record
DIN 02248730: Apo-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id APX Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248730 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73098
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended October 19, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248730
Shortage record checked October 6, 2026

Auro-Alendronate · DIN 02388553 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Alendronate · DIN 02388553 Manufacturer: Auro Pharma Inc.; listing date 2012-09-28 Health Canada: Marketed since 2012-07-26 · brand AURO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388553)

Source record
DIN 02388553: Auro-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id AUR Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388553 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87408
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended July 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388553
Shortage record checked October 6, 2026

Fosamax · DIN 02245329 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Fosamax · DIN 02245329 Manufacturer: Organon Canada Inc.; listing date 2003-01-30 Health Canada: Marketed since 2022-05-03 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245329)

Source record
DIN 02245329: Fosamax Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id OCI Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $12.6250; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245329 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69356
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245329
Shortage record checked October 6, 2026

Jamp Alendronate Sodium · DIN 02500175 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Alendronate Sodium · DIN 02500175 Manufacturer: Jamp Pharma Corporation; listing date 2022-09-29 Health Canada: Marketed since 2022-07-22 · brand JAMP ALENDRONATE SODIUM · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Alendronate Sodium: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02500175)

Source record
DIN 02500175: Jamp Alendronate Sodium Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id JPC Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02500175 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98988
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02500175
Shortage record checked October 6, 2026

M-Alendronate · DIN 02529394 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Alendronate · DIN 02529394 Manufacturer: Mantra Pharma Inc.; listing date 2023-06-30 Health Canada: Marketed since 2026-06-29 · brand M-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529394)

Source record
DIN 02529394: M-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id MAT Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529394 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101860
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529394
Shortage record checked October 6, 2026

NRA-Alendronate · DIN 02523116 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Alendronate · DIN 02523116 Manufacturer: Nora Pharma; listing date 2022-11-30 Health Canada: Marketed since 2022-08-09 · brand NRA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

NRA-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02523116)

Source record
DIN 02523116: NRA-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id NRA Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02523116 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101218
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended May 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02523116
Shortage record checked October 6, 2026

PMS-Alendronate-FC · DIN 02284006 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Alendronate-FC · DIN 02284006 Manufacturer: Pharmascience Inc.; listing date 2007-03-09 Health Canada: Marketed since 2006-08-15 · brand PMS-ALENDRONATE-FC · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Alendronate-FC: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02284006)

Source record
DIN 02284006: PMS-Alendronate-FC Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id PMS Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02284006 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76957
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended November 26, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284006
Shortage record checked October 6, 2026

Riva-Alendronate · DIN 02270889 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Alendronate · DIN 02270889 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2025-12-09 · brand RIVA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Riva-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02270889)

Source record
DIN 02270889: Riva-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id RIA Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02270889 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75626
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended January 17, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02270889
Shortage record checked October 6, 2026

Teva-Alendronate · DIN 02261715 · 70 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Alendronate · DIN 02261715 Manufacturer: Teva Canada Limited; listing date 2005-08-19 Health Canada: Marketed since 2010-06-17 · brand TEVA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02261715)

Source record
DIN 02261715: Teva-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id TEV Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02261715 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74709
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804
Shortage status: resolved shortage (ended December 6, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261715
Shortage record checked October 6, 2026

Apo-Alendronate · DIN 02248728 · 10 mg · tablet

General benefitDormant since March 16, 2021 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Alendronate · DIN 02248728 Manufacturer: Apotex Inc.; listing date 2004-07-20 Health Canada: Dormant since 2021-03-16 · brand APO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Alendronate: Formulary list price $0.50 per unit (the source does not state the unit; exact figure $0.4987). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248728)

Source record
DIN 02248728: Apo-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000232; group id 891; item number 2141; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4987; ministry $0.4987 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248728 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73096
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987 Auro-Alendronate · DIN 02388545 · $0.4987 Fosamax · DIN 02201011 · not recorded Mint-Alendronate · DIN 02394863 · $0.4987 Ran-Alendronate · DIN 02384701 · $0.4987 Sandoz Alendronate · DIN 02288087 · $0.4987 Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248728
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since March 16, 2021 — choose a marketed DIN from the same-category list.

AG-Alendronate · DIN 02485184 · 70 mg · tablet

General benefitDormant since July 30, 2025 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Alendronate · DIN 02485184 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Dormant since 2025-07-30 · brand AG-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Angita pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AG-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02485184)

Source record
DIN 02485184: AG-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id ANG Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485184 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97543
Interchangeable products
Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485184
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 30, 2025 — choose a marketed DIN from the same-category list.

Jamp-Alendronate · DIN 02385031 · 70 mg · tablet

General benefitDormant since July 31, 2024 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Alendronate · DIN 02385031 Manufacturer: Jamp Pharma Corporation; listing date 2012-09-28 Health Canada: Dormant since 2024-07-31 · brand JAMP-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385031)

Source record
DIN 02385031: Jamp-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id JPC Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385031 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87070
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 Mint-Alendronate · DIN 02394871 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended April 15, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385031
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2024 — choose a marketed DIN from the same-category list.

Mint-Alendronate · DIN 02394871 · 70 mg · tablet

General benefitDormant since September 12, 2025 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Alendronate · DIN 02394871 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-03-20 Health Canada: Dormant since 2025-09-12 · brand MINT-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70.0 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Alendronate: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7804). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394871)

Source record
DIN 02394871: Mint-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000426; group id 891; item number 2142; lccId None; manufacturer id MIN Source form: Tab; strength: 70mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7804; ministry $1.7804 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394871 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88003
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804 Alendronate · DIN 02299712 · $1.7804 Alendronate · DIN 02352966 · $1.7804 Alendronate Sodium Tablets · DIN 02381494 · $1.7804 Apo-Alendronate · DIN 02248730 · $1.7804 Auro-Alendronate · DIN 02388553 · $1.7804 Fosamax · DIN 02245329 · $1.7804 Jamp Alendronate Sodium · DIN 02500175 · $1.7804 Jamp-Alendronate · DIN 02385031 · $1.7804 M-Alendronate · DIN 02529394 · $1.7804 NRA-Alendronate · DIN 02523116 · $1.7804 PMS-Alendronate-FC · DIN 02284006 · $1.7804 Riva-Alendronate · DIN 02270889 · $1.7804 Sandoz Alendronate · DIN 02288109 · $1.7804 Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: active shortage (reported January 18, 2024, estimated to end June 30, 2026, last updated June 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394871
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 12, 2025 — choose a marketed DIN from the same-category list.

Alendronate Sodium Tablets · DIN 02381478 · 5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since September 18, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Alendronate Sodium Tablets · DIN 02381478 Manufacturer: Accord Healthcare Inc.; listing date 2012-08-27 Health Canada: Dormant since 2026-09-18 · brand ACH-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02381478)

Source record
DIN 02381478: Alendronate Sodium Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000294; group id 891; item number 2140; lccId None; manufacturer id ACH Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0370; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02381478 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86732
Interchangeable products
Apo-Alendronate · DIN 02248727 · not recorded Fosamax · DIN 02233055 · not recorded Teva-Alendronate · DIN 02248251 · not recorded
Shortage status: active shortage (reported July 12, 2024, last updated July 13, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381478
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 18, 2026 — choose a marketed DIN from the same-category list.

Apo-Alendronate · DIN 02248727 · 5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since July 7, 2021 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Alendronate · DIN 02248727 Manufacturer: Apotex Inc.; listing date 2007-10-03 Health Canada: Dormant since 2021-07-07 · brand APO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248727)

Source record
DIN 02248727: Apo-Alendronate Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000294; group id 891; item number 2140; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0370; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248727 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73095
Interchangeable products
Alendronate Sodium Tablets · DIN 02381478 · not recorded Fosamax · DIN 02233055 · not recorded Teva-Alendronate · DIN 02248251 · not recorded
Shortage status: discontinued (December 20, 2019, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248727
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 7, 2021 — choose a marketed DIN from the same-category list.

Mint-Alendronate · DIN 02394863 · 10 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.Discontinued August 1, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Alendronate · DIN 02394863 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-03-20 Health Canada: Cancelled post market since 2018-08-01 · brand MINT-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10.0 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Alendronate: Formulary list price $0.50 per unit (the source does not state the unit; exact figure $0.4987). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394863)

Source record
DIN 02394863: Mint-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000232; group id 891; item number 2141; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4987; ministry $0.4987 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394863 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88002
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987 Apo-Alendronate · DIN 02248728 · $0.4987 Auro-Alendronate · DIN 02388545 · $0.4987 Fosamax · DIN 02201011 · not recorded Ran-Alendronate · DIN 02384701 · $0.4987 Sandoz Alendronate · DIN 02288087 · $0.4987 Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394863
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 1, 2018 — choose a marketed DIN from the same-category list.

Fosamax · DIN 02233055 · 5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2010 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Fosamax · DIN 02233055 Manufacturer: Merck Frosst Canada Ltd.; listing date 2007-10-03 Health Canada: Cancelled post market since 2010-07-30 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fosamax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02233055)

Source record
DIN 02233055: Fosamax Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000294; group id 891; item number 2140; lccId None; manufacturer id MFC Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02233055 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52648
Interchangeable products
Alendronate Sodium Tablets · DIN 02381478 · not recorded Apo-Alendronate · DIN 02248727 · not recorded Teva-Alendronate · DIN 02248251 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02233055
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2010 — choose a marketed DIN from the same-category list.

Teva-Alendronate · DIN 02248251 · 5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.Discontinued July 29, 2021 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Teva-Alendronate · DIN 02248251 Manufacturer: Teva Canada Limited; listing date 2007-10-03 Health Canada: Cancelled post market since 2021-07-29 · brand TEVA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248251)

Source record
DIN 02248251: Teva-Alendronate Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000294; group id 891; item number 2140; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0370; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248251 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72588
Interchangeable products
Alendronate Sodium Tablets · DIN 02381478 · not recorded Apo-Alendronate · DIN 02248727 · not recorded Fosamax · DIN 02233055 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248251
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 29, 2021 — choose a marketed DIN from the same-category list.

Fosamax · DIN 02201011 · 10 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.Discontinued November 10, 2011 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Fosamax · DIN 02201011 Manufacturer: Merck Frosst Canada Ltd.; listing date 2000-11-30 Health Canada: Cancelled post market since 2011-11-10 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fosamax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02201011)

Source record
DIN 02201011: Fosamax Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000232; group id 891; item number 2141; lccId None; manufacturer id MFC Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02201011 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19643
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987 Apo-Alendronate · DIN 02248728 · $0.4987 Auro-Alendronate · DIN 02388545 · $0.4987 Mint-Alendronate · DIN 02394863 · $0.4987 Ran-Alendronate · DIN 02384701 · $0.4987 Sandoz Alendronate · DIN 02288087 · $0.4987 Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02201011
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 10, 2011 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M05B, M05BA): coverage varies; not interchangeable

  • Risedronate (Actonel DR): general benefit, not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, not a benefit
  • Etidronate (Didronel): limited Use 236, 237, not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, not a benefit
  • Pamidronate (Aredia): not a benefit
  • Denosumab (Stoboclo): limited Use 686, limited Use 687, 688
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 77 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: osteoporosis in men, osteoporosis in postmenopausal women
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. RISEDRONATE SODIUM · General benefit (20), Listed, not a benefit (3) For the prevention of osteoporosis in postmenopausal women who are at risk of developing osteoporosis, ACTONEL preserves or increases BMD at sites of clinical importance. PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph  the treatment of osteoporosis in men, to improve bone mineral density PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph  The treatment of osteoporosis in postmenopausal women PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph RALOXIFENE HCL · Limited Use, codes 373 INDICATIONS AND CLINICAL USE APO-RALOXIFENE (raloxifene hydrochloride) is indicated for the treatment and prevention of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00002184.PDF; date not captured; DIN 02279215; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS FOSAMAX® (alendronate sodium) is indicated for: • The treatment of osteoporosis in postmenopausal women. o For the treatment of osteoporosis in postmenopausal women, FOSAMAX® increases bone mass and prevents fractures, including those of the hip and spine (vertebral compression fractures). • The treatment of osteoporosis in men. o For the treatment of osteoporosis in men, FOSAMAX® increases bone mass and reduces the incidence of fractures. • The prevention of osteoporosis in postmenopausal women1 o For the prevention of osteoporosis, alendronate sodium may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. • The treatment and prevention of glucocorticoid-induced osteoporosis in men and women.1 o Alendronate sodium is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. 1 Although alendronate tablets 5 mg, 10 mg, a… https://pdf.hres.ca/dpd_pm/00071922.PDF PM date: not printed or not captured Source product: FOSAMAX; DIN 02245329; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS FOSAVANCE® (alendronate sodium/cholecalciferol) is indicated for: • The treatment of osteoporosis in postmenopausal women. • The treatment of osteoporosis in men. For the treatment of osteoporosis, the alendronate sodium component of FOSAVANCE® increases bone mass and can prevent fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2.5 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. Patients suffering from osteoporosis are at an increased risk for vitamin D insufficiency, especially those over the age of 70 years, home bound, or chronically ill, and may need to receive vitamin D supplementation in addition to that provided in FOSAVANCE® (see 4.4 DOSAGE AND ADMINISTRATION, Administration). Those living in high latitudes (including most of Canada) may also need additional supplementation. An adequate calcium intake is also required. Patients with gastrointestinal malabsorption may not adequately absorb vitamin D 3 and will also require further supplementation. FOSAVANCE® alone should no… https://pdf.hres.ca/dpd_pm/00071923.PDF PM date: not printed or not captured Source product: FOSAVANCE; DIN 02276429; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Alendronate Sodium Tablets · DIN 02381486 Shortage status: active shortage (reported 2024-04-12, last updated 2024-04-13) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381486

Check this DIN again

Apo-Alendronate · DIN 02248728 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248728

Check this DIN again

Mint-Alendronate · DIN 02394871 Shortage status: active shortage (reported 2024-01-18, estimated to end 2026-06-30, last updated 2026-06-17); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394871

Check this DIN again

Alendronate Sodium Tablets · DIN 02381478 Shortage status: active shortage (reported 2024-07-12, last updated 2024-07-13) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381478

Check this DIN again

Apo-Alendronate · DIN 02248727 Shortage status: discontinued (2019-12-20, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248727

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Alendronate Sodium Tablets, Apo-Alendronate, Fosamax, Teva-Alendronate: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026